Innervace, a spun out of the University of Pennsylvania, is a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry.
Innervace is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction.
Innervace was founded in 2020 by Kacy Cullen and Douglas Smith at Penn. The company is headquartered in New York, New York.
Innervace's technology acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury.
Innervace's lead clinical product is a tissue-engineered nigrostriatal pathway (TE-NSP) that mimics the lost nigrostriatal pathway in patients with Parkinson’s disease (PD).
Innervace's PD cell therapies infuse dopaminergic neurons straight into the striatum, potentially creating uncontrolled dopamine release. TE-NSP recapitulate the lost circuitry in PD patients, allowing for refined and controlled dopamine release.
Innervace has raised $40M in a Series A funding on Sep 08, 2022. The round was led by Deerfield Management, with participation from IP Group, Penn Medicine, WARF Ventures, and BioAdvance.